Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B‐Cell Hematological Malignancies

A fixed‐dose subcutaneous (s.c.) formulation of the anti‐CD20 antibody, rituximab, has been developed to address safety, infusion time, and patient comfort concerns relating to intravenous (i.v.) dosing, and has been approved based upon a pharmacokinetic (PK)–clinical bridging strategy, which demons...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamois, Candice, Gibiansky, Ekaterina, Gibiansky, Leonid, Chavanne, Clarisse, Morcos, Peter N., McIntyre, Christine, Barrett, Martin, Lundberg, Linda, Zharkov, Artem, Boehnke, Axel, Frey, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597022/
https://www.ncbi.nlm.nih.gov/pubmed/34041738
http://dx.doi.org/10.1002/cpt.2308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597022/
https://www.ncbi.nlm.nih.gov/pubmed/34041738
http://dx.doi.org/10.1002/cpt.2308

Ejemplares similares